NCT06207656View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2029

Conditions
Colorectal Cancer
Interventions
DRUG

EBC

"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."

Trial Locations (1)

28046

RECRUITING

Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD), Madrid

All Listed Sponsors
collaborator

Merck, S.L., Spain

INDUSTRY

collaborator

Pierre Fabre Ibérica, S.A.

INDUSTRY

lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER

NCT06207656 - Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter